https://pharmacopedia.wiki/api.php?action=feedcontributions&feedformat=atom&user=MediaWiki+default
Pharmacopedia - User contributions [en]
2026-05-28T08:17:23Z
User contributions
MediaWiki 1.46.0-beta
https://pharmacopedia.wiki/index.php?title=Module:TopCategories&diff=3361
Module:TopCategories
2026-05-14T19:47:02Z
<p>MediaWiki default: Create TopCategories Lua module for dynamic top-10 list</p>
<hr />
<div>local p = {}<br />
<br />
local categories = {<br />
'Addiction Medicine', 'Amphetamines', 'Anesthetics', 'Anti-Dementia Medicines',<br />
'Anticonvulsants / Antiepileptics', 'Antidepressants', 'Antihistamines',<br />
'Antiparkinsonian Medicines', 'Antipsychotics / Neuroleptics',<br />
'Anxiolytics & Sedative-Hypnotics', 'Arylcyclohexylamines', 'Barbiturates',<br />
'Benzodiazepines', 'Cannabinoids', 'Cathinones',<br />
'Classical Psychedelics (Serotonergic)', 'Deliriants', 'Dissociatives',<br />
'Empathogens / Entactogens', 'Ergotamines',<br />
'Eugeroics (Wakefulness-Promoting Agents)', 'GABAergics', 'Local Anesthetics',<br />
'Lysergamides', 'Methylphenidates (Phenidates)', 'Migraine Medicines',<br />
'Monoamine Oxidase Inhibitors (MAOIs)', 'Mood Stabilizers',<br />
'Muscle Relaxants (CNS-acting)', 'NBOMe / NBOH series', 'Natural opioids',<br />
'Nootropics', 'Opioid Antagonists', 'Opioids', 'Orexin Receptor Antagonists',<br />
'Phenethylamines', 'Psychedelics', 'Pyrrolidinophenones',<br />
'Research Materials', 'Second-Generation Antipsychotics (SGAs / Atypicals)',<br />
'Selective Serotonin Reuptake Inhibitors (SSRIs)', 'Semisynthetic opioids',<br />
'Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)',<br />
'Stimulants & Wake-Promoting Agents', 'Synthetic opioids',<br />
'Tricyclic Antidepressants (TCAs)', 'Triptans (5-HT1B/1D Agonists)',<br />
'Tryptamines', 'Xanthines', 'Z-Drugs (Non-Benzodiazepine Hypnotics)',<br />
}<br />
<br />
function p.list(frame)<br />
local counts = {}<br />
for _, cat in ipairs(categories) do<br />
local n = mw.site.stats.pagesInCategory(cat, 'pages')<br />
if n > 0 then<br />
table.insert(counts, {name = cat, count = n})<br />
end<br />
end<br />
-- Sort descending by count to pick top 10<br />
table.sort(counts, function(a, b) return a.count > b.count end)<br />
local top10 = {}<br />
for i = 1, math.min(10, #counts) do<br />
table.insert(top10, counts[i])<br />
end<br />
-- Re-sort top 10 alphabetically<br />
table.sort(top10, function(a, b) return a.name < b.name end)<br />
local lines = {}<br />
for _, item in ipairs(top10) do<br />
table.insert(lines, '* [[:Category:' .. item.name .. '|' .. item.name .. ']]')<br />
end<br />
return table.concat(lines, '\n')<br />
end<br />
<br />
return p</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Mixed_amphetamine_salts&diff=3350
Mixed amphetamine salts
2026-05-14T15:18:40Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Mixed amphetamine salts<br />
| brand = Adderall, Adderall XR, Mydayis<br />
| structure = Amphetamine-white.svg<br />
| classes = Psychostimulant, Amphetamine<br />
| uses = <vote slug="inattention">Inattention</vote>, <vote slug="narcolepsy">Narcolepsy</vote>, <vote slug="hyperactivity">Hyperactivity</vote>, <vote slug="impulsivity">Impulsivity</vote>, <vote slug="irritability">Irritability</vote><br />
| starting_dose = 2.5 mg IR, 5 mg XR, or 12.5mg Mydayis<br />
| preparations = IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg<br />
| fda_max = <br />
| routes = Oral<br />
| onset = IR: 30–60 min; XR: 1–2 h to peak effect<br />
| duration = IR 4–6 h; XR 10–12 h; Mydayis 14–16 h<br />
| halflife = D-amphetamine ~10 h; L-amphetamine ~13 h (adults)<br />
| bioavailability = ~75–90% (oral)<br />
| pregnancy = Category C<br />
| legal = Schedule II<br />
| mechanism = TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport — net release of dopamine and norepinephrine<br />
| intro = '''Mixed amphetamine salts (MAS)''' — marketed primarily as '''Adderall''' — is a 3:1 mixture of dextroamphetamine and levoamphetamine salts (dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate). <br />
Amphetamine was first synthesized in 1887 by Lazăr Edeleanu, then developed as a medicine in the late 1920s. "Adderall" was approved by the FDA in 1996, and has since become one of the most popular medicines in the United States. Adderall/MAS is FDA-approved for attention-deficit hyperactivity disorder and narcolepsy. It is listed in Schedule II of the Controlled Substances Act, and so is tightly regulated in the United States as well as many other countries around the world.<br />
| indications = <indication ref="adhd" author="MDElliottMD"/><br />
<indication ref="narcolepsy" author="MDElliottMD"/><br />
<indication ref="trd-augment" author="MDElliottMD"><br />
Off-label.<br />
</indication><br />
<indication ref="shift-work" author="MDElliottMD"><br />
Off-label.<br />
</indication><br />
<indication ref="chronic-illness-cog" author="MDElliottMD"><br />
Off-label.<br />
</indication><br />
<br />
<indication ref="impulsivity" author="MDElliottMD"/><br />
<br />
<indication ref="distractibility" author="MDElliottMD"><br />
Impoved sustained attention by decreasing distractibility<br />
</indication><br />
| dosing = <titration slug="typical-adult" title="Typical Adult" author="MDElliottMD"><br />
Start at 5 mg XR; may increase by 5 mg each day until the desired effect is reached, up to 30 mg XR to start, and up to 60 mg XR eventually if necessary, in 10 mg increments.<br />
<br />
Occasionally can go higher if no notable effects (good or bad) at 60 mg — proceed with caution.<br />
<br />
If not long enough acting: add a tail dose of Adderall IR at [XR dose]/2.<br />
If too long acting (e.g. disrupting sleep): switch to IR entirely (again at half the XR dose).<br />
</titration><br />
| effects = <br />
* <effect ref="attention" author="MDElliottMD">Improved sustained attention, particularly on uninteresting things.</effect><br />
* <effect ref="reduced-impulsivity" author="MDElliottMD"/><br />
* <effect ref="wakefulness" author="MDElliottMD"/><br />
* <effect ref="motivation" author="MDElliottMD"/><br />
* <effect ref="euphoria" author="MDElliottMD"/><br />
* <effect ref="decreased-appetite" author="MDElliottMD"></effect><br />
* <effect ref="dry-mouth" author="MDElliottMD"/><br />
* <effect ref="hr-bp-elevation" author="MDElliottMD"/><br />
* <effect ref="bruxism" author="MDElliottMD"/><br />
* <effect ref="insomnia" author="MDElliottMD">(with proper am dosing)</effect><br />
* <effect ref="irritability" author="MDElliottMD"/><br />
* <effect ref="anxiety" author="MDElliottMD"/><br />
* <effect ref="headache" author="MDElliottMD"/><br />
* <effect ref="weight-loss" author="MDElliottMD"/><br />
* <effect ref="palpitations" author="MDElliottMD"/><br />
* <effect ref="stereotypies" author="MDElliottMD">Repetitive movements, e.g. skin picking, muscle twitches, tics</effect><br />
* <effect ref="cardiac-event" author="MDElliottMD"></effect><br />
* <effect ref="agitation" author="MDElliottMD"/><br />
* <effect ref="psychosis" author="MDElliottMD"></effect><br />
* <effect ref="mania" author="MDElliottMD"></effect><br />
* <effect ref="dependence" author="MDElliottMD"></effect><br />
* <effect ref="tolerance" author="MDElliottMD"></effect><br />
* <effect ref="growth-suppression" author="MDElliottMD">(well documented effect with chronic use in children)</effect><br />
* <effect ref="serotonin-syndrome" author="MDElliottMD">Especially in combination with MAOIs</effect><br />
* <effect ref="vasculopathy" author="MDElliottMD">Raynaud-like phenomenon, rare digital ischemia.</effect><br />
* <effect ref="seizure" author="MDElliottMD"></effect><br />
* <effect ref="hyperthermia" author="MDElliottMD">Risk in hot environments or with vigorous exercise.</effect><br />
* <effect ref="withdrawal" author="MDElliottMD">Low motivation, low mood, hypersomnia, increased appetite on abrupt discontinuation.</effect><br />
* <effect ref="urinary-retention" author="MDElliottMD">Difficult/slow urination</effect><br />
| pk_absorption = Excellent oral bioavailability — sources report ">75%" to "~90%". Food does not significantly affect total absorption but can delay peak concentration.<br />
| pk_distribution = Volume of distribution ~4 L/kg; plasma protein binding less than 20%. Crosses the blood–brain barrier and placenta.<br />
| pk_metabolism = Amphetamine is oxidized to 4-hydroxyamphetamine, α-hydroxyamphetamine, or norephedrine. Norephedrine and 4-hydroxyamphetamine are active metabolites and are further metabolized to 4-hydroxy-norephedrine. Deamination of α-hydroxyamphetamine yields phenylacetone, which is metabolized to benzoic acid and conjugated to its glucuronide and hippuric acid. '''CYP2D6''' is crucial for amphetamine metabolism; genetic polymorphism causes significant inter-patient variability in clearance. Amphetamine itself inhibits monoamine oxidase (MAO), and both CYP1A2 and CYP3A4 contribute to its metabolism.<ref>https://www.ncbi.nlm.nih.gov/sites/books/NBK507808/</ref><br />
| pk_elimination = Primarily renal — ~30–40% recovered as unchanged amphetamine, the rest as metabolites. Due to its pK<sub>a</sub> of 9.9, urinary elimination is highly pH-dependent: alkaline urine reduces ionization and decreases renal clearance, while acidic urine and high flow rates accelerate clearance via active tubular secretion. '''Half-life:''' D-enantiomer 9 h (children 6–12 y), 11 h (adolescents 13–17 y), 10 h (adults); L-enantiomer 11 h, 13–14 h, 13 h respectively.<br />
| pharmacodynamics = Amphetamine purportedly works via several converging mechanisms at monoaminergic terminals:<br />
* '''Trace amine-associated receptor 1 (TAAR1) agonism''' — activates TAAR1 in monoaminergic neurons, triggering PKA/PKC signaling that phosphorylates the dopamine and norepinephrine transporters (DAT, NET), causing them to internalize and reverse direction.<br />
* '''VMAT2 substrate''' — enters the presynaptic terminal, displaces dopamine and norepinephrine from vesicles into the cytoplasm.<br />
* '''Reverse transport via DAT/NET''' — the elevated cytoplasmic monoamine pool is then ejected into the synaptic cleft via the now-reversed transporters. '''This is the primary mechanism of action — release, not reuptake inhibition.'''<br />
* '''Weak reuptake inhibition''' at DAT and NET (secondary to release).<br />
* '''MAO inhibition''' at higher concentrations, slowing presynaptic catabolism of monoamines.<br />
* '''Serotonergic effects''' at high or supratherapeutic doses (relevant to overdose and serotonin syndrome risk).<br />
<br />
The net result is a robust increase in synaptic dopamine and norepinephrine in prefrontal cortex, striatum, and nucleus accumbens — underlying both therapeutic (attention, executive function, wakefulness) and reinforcing (euphoria, abuse liability) effects.<br />
| interactions = Minimal in practice. Caution with other psychostimulants, including caffeine. metabolized by 2D6, so relevant caution applies.<br />
<pharmaInteractions/><br />
| pregnancy_details = [https://www.ncbi.nlm.nih.gov/books/NBK501307/ Category C]. Crosses the placenta. Prenatal amphetamine exposure has been associated with low birth weight, premature delivery, and neonatal withdrawal (agitation, dysphoria, lassitude). Long-term neurodevelopmental outcomes from prescribed therapeutic exposure are less clear and likely modest, but illicit-dose exposure is associated with significant developmental impact. Decision should be individualized; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in clinically significant amounts — breastfeeding generally discouraged.<br />
| monitoring = * Baseline: cardiovascular history, weight/height, mental health history (especially for psychosis/bipolar/substance use risk), (optional) blood pressure, (optional) heart rate,<br />
* At each visit: efficacy, side effects, general well-being<br />
* Periodically reassess continued need; consider drug holidays to assess ongoing benefit<br />
* Sleep quality (insomnia is dose-limiting)<br />
| counseling = * Take first thing in the morning to minimize insomnia; avoid (late) afternoon dosing.<br />
* '''Do not crush, chew, or split Adderall XR or Mydayis capsules''' — disrupts the controlled-release mechanism. (Capsules may be opened and sprinkled on applesauce if needed.)<br />
* Take with or without food; high-acid beverages (orange juice, vitamin C) may reduce absorption.<br />
* Stay well-hydrated, especially in heat or during exercise.<br />
* Eat regular meals despite appetite suppression.<br />
* Report any chest pain, palpitations, severe agitation, hallucinations, or signs of poor circulation in extremities.<br />
* Sudden discontinuation can cause a fatigue/depression "crash" — plan for it.<br />
* Take caution: make increase bowel motility and increase risk of expelled fecal content.<br />
| anecdotes = <br />
| seealso = [[Dextroamphetamine]], [[Lisdexamfetamine]], [[Methylphenidate]], [[Dexmethylphenidate]], [[Modafinil]], [[Atomoxetine]], [[Methamphetamine]]<br />
| references = <br />
}}<br />
<br />
[[Category:Stimulants & Wake-Promoting Agents]]<br />
[[Category:Amphetamines]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Sertraline&diff=3347
Sertraline
2026-05-14T15:14:58Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Sertraline<br />
| brand = Zoloft, Lustral<br />
| structure = Sertraline.svg<br />
| classes = SSRI, Antidepressant, Anxiolytic<br />
| mechanism = SSRI; weak DRI<br />
| uses = Depression, anxiety disorders, OCD, PTSD, panic disorder<br />
| formula = C17H17Cl2N<br />
| routes = Oral<br />
| onset = 2–4 weeks for full effect<br />
| duration = <br />
| halflife = 26 hours (parent); norsertraline 62–104 hours<br />
| bioavailability = ~44%<br />
| pregnancy = Category C<br />
| legal = Rx-only<br />
| intro = '''Sertraline''' is a selective serotonin reuptake inhibitor (SSRI) commonly prescribed for depression, anxiety disorders, OCD, PTSD, and panic disorder. In the US, it is one of the [https://www.definitivehc.com/resources/healthcare-insights/top-antidepressants-by-prescription-volume most frequently utilized SSRIs at this time].<br />
| pharmacokinetics = Well-absorbed orally, ~44% bioavailability. Metabolized hepatically via CYP3A4/CYP2C19/CYP2D6 to N-desmethylsertraline (less active). Half-life ~26h; steady state in ~1 week.<br />
| pharmacodynamics = Highly selective inhibitor of the serotonin reuptake transporter (SERT). Mild dopamine reuptake inhibition at higher doses. Minimal affinity for muscarinic, histaminic, or adrenergic receptors — hence cleaner adverse effect profile than TCAs.<br />
| indications = * Major depressive disorder<br />
* Generalized anxiety disorder<br />
* Obsessive-compulsive disorder<br />
* Post-traumatic stress disorder<br />
* Panic disorder<br />
* Premenstrual dysphoric disorder<br />
| dosing = Start 25–50 mg PO daily. Titrate by 25–50 mg every 1–2 weeks based on response. Typical effective dose 50–200 mg/day; max 200 mg/day.<br />
| effects = <br />
* <effect ref="mood-improvement">Onset typically 2–4 weeks.</effect><br />
* <effect ref="anxiolysis">Onset typically 2–4 weeks.</effect><br />
* <effect ref="ocd-improvement">Delayed onset; full benefit often takes 4+ weeks.</effect><br />
* <effect ref="nausea">Often improves over the first 1–2 weeks.</effect><br />
* <effect ref="diarrhea"/><br />
* <effect ref="sexual-dysfunction">Decreased libido, delayed orgasm, anorgasmia. Can persist long-term in some patients (PSSD).</effect><br />
* <effect ref="insomnia"/><br />
* <effect ref="somnolence"/><br />
* <effect ref="sweating"/><br />
* <effect ref="serotonin-syndrome">Especially with other serotonergic agents (triptans, tramadol, MAOIs, linezolid).</effect><br />
* <effect ref="qt-prolongation">Dose-dependent; check ECG in cardiac risk.</effect><br />
* <effect ref="hyponatremia">Especially in elderly patients.</effect><br />
* <effect ref="bleeding-risk">Particularly with concurrent NSAIDs or anticoagulants.</effect><br />
* <effect ref="suicidality">Black box warning in patients under 25; close monitoring in first 4 weeks.</effect><br />
* <effect ref="discontinuation-syndrome">"Brain zaps," dizziness, irritability, flu-like symptoms with abrupt cessation. Taper to avoid.</effect><br />
| adverse = Serotonin syndrome (especially with other serotonergic agents), QT prolongation at high doses, hyponatremia (SIADH, esp. elderly), bleeding risk, suicidality warning in young adults, discontinuation syndrome.<br />
| interactions = MAOIs (serotonin syndrome — contraindicated), triptans, tramadol, linezolid, lithium, NSAIDs/anticoagulants (bleeding), CYP2D6 substrates.<br />
<pharmaInteractions/><br />
| pregnancy_details = Category C. SSRIs in third trimester associated with persistent pulmonary hypertension of the newborn (PPHN) and neonatal adaptation syndrome. Risk-benefit decision; sertraline often preferred in pregnancy among SSRIs.<br />
| monitoring = Mood/suicidality (especially first 4 weeks), sodium (elderly), QT in cardiac risk, response and side effects.<br />
| counseling = Take with or without food. Effect emerges over 2–4 weeks. Don't stop abruptly — taper to avoid withdrawal. Report serotonin-syndrome symptoms.<br />
| anecdotes = <br />
| seealso = [[Fluoxetine]], [[Paroxetine]], [[Citalopram]], [[Escitalopram]]<br />
| references = <br />
}}<h2 id="Pharmacokinetics">Pharmacokinetics</h2><br />
Well-absorbed orally, ~44% bioavailability. Metabolized hepatically via CYP3A4/CYP2C19/CYP2D6 to N-desmethylsertraline (less active). Half-life ~26h; steady state in ~1 week.<h2 id="Pharmacodynamics">Pharmacodynamics</h2><br />
Highly selective inhibitor of the serotonin reuptake transporter (SERT). Mild dopamine reuptake inhibition at higher doses. Minimal affinity for muscarinic, histaminic, or adrenergic receptors — hence cleaner adverse effect profile than TCAs.<h2 id="Indications">Indications</h2><br />
*Major depressive disorder<br />
*Generalized anxiety disorder<br />
*Obsessive-compulsive disorder<br />
*Post-traumatic stress disorder<br />
*Panic disorder<br />
*Premenstrual dysphoric disorder<h2 id="Dosing">Dosing and titration</h2><br />
Start 25–50 mg PO daily. Titrate by 25–50 mg every 1–2 weeks based on response. Typical effective dose 50–200 mg/day; max 200 mg/day.<h2 id="Effects">Effects</h2><span></span><br />
''Therapeutic:'' improved mood, reduced anxiety, fewer obsessive thoughts (delayed 2–4 weeks).<br />
<br />
<span></span><br />
<br />
''Common adverse:'' nausea, diarrhea, sexual dysfunction, insomnia, somnolence, sweating.<h2 id="Adverse">Adverse effects</h2><br />
Serotonin syndrome (especially with other serotonergic agents), QT prolongation at high doses, hyponatremia (SIADH, esp. elderly), bleeding risk, suicidality warning in young adults, discontinuation syndrome.<h2 id="Contraindications">Contraindications</h2><br />
MAOIs (within 14 days), pimozide, severe hepatic impairment. Caution: bipolar disorder (mood switching risk), seizure disorders.<h2 id="Interactions">Interactions</h2><br />
MAOIs (serotonin syndrome — contraindicated), triptans, tramadol, linezolid, lithium, NSAIDs/anticoagulants (bleeding), CYP2D6 substrates.<h2 id="Pregnancy">Pregnancy and lactation</h2><br />
Category C. SSRIs in third trimester associated with persistent pulmonary hypertension of the newborn (PPHN) and neonatal adaptation syndrome. Risk-benefit decision; sertraline often preferred in pregnancy among SSRIs.<h2 id="Monitoring">Monitoring</h2><br />
Mood/suicidality (especially first 4 weeks), sodium (elderly), QT in cardiac risk, response and side effects.<h2 id="Counseling">Patient counseling</h2><br />
Take with or without food. Effect emerges over 2–4 weeks. Don't stop abruptly — taper to avoid withdrawal. Report serotonin-syndrome symptoms.<h2 id="SeeAlso">See also</h2><span></span><br />
[[Fluoxetine]], [[Paroxetine]], [[Citalopram]], [[Escitalopram]]<br />
<br />
[[Category:Antidepressants]]<br />
[[Category:Selective Serotonin Reuptake Inhibitors (SSRIs)]]<br />
[[Category:Medicines]]<br />
<h2 id="Pharmacokinetics">Pharmacokinetics</h2><br />
Well-absorbed orally, ~44% bioavailability. Metabolized hepatically via CYP3A4/CYP2C19/CYP2D6 to N-desmethylsertraline (less active). Half-life ~26h; steady state in ~1 week.<h2 id="Pharmacodynamics">Pharmacodynamics</h2><br />
Highly selective inhibitor of the serotonin reuptake transporter (SERT). Mild dopamine reuptake inhibition at higher doses. Minimal affinity for muscarinic, histaminic, or adrenergic receptors — hence cleaner adverse effect profile than TCAs.<h2 id="Indications">Indications</h2><br />
*Major depressive disorder<br />
*Generalized anxiety disorder<br />
*Obsessive-compulsive disorder<br />
*Post-traumatic stress disorder<br />
*Panic disorder<br />
*Premenstrual dysphoric disorder<h2 id="Dosing">Dosing and titration</h2><br />
Start 25–50 mg PO daily. Titrate by 25–50 mg every 1–2 weeks based on response. Typical effective dose 50–200 mg/day; max 200 mg/day.<h2 id="Effects">Effects</h2><span></span><br />
''Therapeutic:'' improved mood, reduced anxiety, fewer obsessive thoughts (delayed 2–4 weeks).<br />
<br />
<span></span><br />
<br />
''Common adverse:'' nausea, diarrhea, sexual dysfunction, insomnia, somnolence, sweating.<h2 id="Adverse">Adverse effects</h2><br />
Serotonin syndrome (especially with other serotonergic agents), QT prolongation at high doses, hyponatremia (SIADH, esp. elderly), bleeding risk, suicidality warning in young adults, discontinuation syndrome.<h2 id="Contraindications">Contraindications</h2><br />
MAOIs (within 14 days), pimozide, severe hepatic impairment. Caution: bipolar disorder (mood switching risk), seizure disorders.<h2 id="Interactions">Interactions</h2><br />
MAOIs (serotonin syndrome — contraindicated), triptans, tramadol, linezolid, lithium, NSAIDs/anticoagulants (bleeding), CYP2D6 substrates.<h2 id="Pregnancy">Pregnancy and lactation</h2><br />
Category C. SSRIs in third trimester associated with persistent pulmonary hypertension of the newborn (PPHN) and neonatal adaptation syndrome. Risk-benefit decision; sertraline often preferred in pregnancy among SSRIs.<h2 id="Monitoring">Monitoring</h2><br />
Mood/suicidality (especially first 4 weeks), sodium (elderly), QT in cardiac risk, response and side effects.<h2 id="Counseling">Patient counseling</h2><br />
Take with or without food. Effect emerges over 2–4 weeks. Don't stop abruptly — taper to avoid withdrawal. Report serotonin-syndrome symptoms.<h2 id="SeeAlso">See also</h2><span></span><br />
[[Fluoxetine]], [[Paroxetine]], [[Citalopram]], [[Escitalopram]]<br />
[[Category:Medicines]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Fluoxetine&diff=3346
Fluoxetine
2026-05-14T15:14:58Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Fluoxetine<br />
| brand = Prozac<br />
| structure = Fluoxwhite.svg<br />
| classes = SSRI, Anxiolytic, Antidepressant<br />
| uses = <vote slug="anxiety-use">Anxiety</vote>, <vote slug="premature-ejaculation-use">Premature ejaculation</vote>, <vote slug="low-mood-use">Low mood</vote><br />
| starting_dose = 10 mg<br />
| preparations = 10 mg, 20 mg, 40 mg caps<br />
| fda_max = 40 mg/d<br />
| routes = Oral<br />
| onset = <br />
| duration = Very long<br />
| halflife = 1–4 days (7–15 days for norfluoxetine)<br />
| bioavailability = 70–90% (oral)<br />
| pregnancy = Category C<ref name="lactmed">https://www.ncbi.nlm.nih.gov/books/NBK501186/</ref><br />
| legal = Rx-only in US<br />
| mechanism = TrkB/BDNF<ref name="trkb">https://pmc.ncbi.nlm.nih.gov/articles/PMC9666396/</ref> <vote slug="ssri-claim">Fluoxetine is a selective serotonin reuptake inhibitor.</vote><br />
| intro = Fluoxetine was the first of a long line of SSRIs. It is notable for its extremely long half-life and relative lack of withdrawal syndrome. It can also be useful in helping taper and discontinue other SxRI medicines.<br />
| indications = <indication ref="depression" author="MDElliottMD"/><br />
<indication ref="anxiety-disorders" author="MDElliottMD"><br />
Including generalized anxiety, panic, and social anxiety.<br />
</indication><br />
<indication ref="panic" author="MDElliottMD"/><br />
<indication ref="social-anxiety" author="MDElliottMD"/><br />
<indication ref="ocd" author="MDElliottMD"/><br />
<indication ref="ptsd" author="MDElliottMD"><br />
Potentially.<br />
</indication><br />
| dosing = <titration slug="standard" author="MDElliottMD" title="Standard adult or child"><br />
Start no higher than 10 mg for the first dose. May increase by 10 mg every 2–12 weeks, or remain at 10 mg if the response is adequate, up to a typical starting maximum of 40 mg. Absolute max: 80 mg.<br />
</titration><br />
<br />
<titration slug="ocd" author="MDElliottMD" title="OCD"><br />
Start at 10 mg daily; increase by 10–20 mg every 2–6 weeks, up to 80 mg. OCD typically requires elevated doses (60–80 mg).<br />
</titration><br />
| effects = <br />
* <effect ref="anxiolysis" author="MDElliottMD">Classically starting at 3–4 weeks and improving for another 8–12.</effect><br />
* <effect ref="delayed-ejaculation" author="MDElliottMD"/><br />
* <effect ref="mood-enhancement" author="MDElliottMD"/><br />
* <effect ref="nausea" author="MDElliottMD">Common, often improves over 1–2 weeks.</effect><br />
* <effect ref="decreased-libido" author="MDElliottMD"/><br />
* <effect ref="temporary-erectile-dysfunction" author="MDElliottMD"/><br />
* <effect ref="persistent-sexual-dysfunction" author="MDElliottMD">Historically [https://pmc.ncbi.nlm.nih.gov/articles/PMC11450419/ associated with SSRIs].</effect><br />
<br />
<effect ref="anorgasmia" author="MDElliottMD"/><br />
| pk_absorption = 70–90%<ref name="statpearls">https://www.ncbi.nlm.nih.gov/books/NBK459223/</ref> oral bioavailability.<br />
| pk_distribution = Fluoxetine has plasma protein binding of approximately 94.5%, bound to albumin and alpha-1 glycoprotein. Fluoxetine readily crosses the blood–brain barrier, with a brain-to-plasma ratio of 2.6:1 in humans. The volume of distribution (Vd) of fluoxetine and its metabolite ranges between 20 to 42 L/kg. Some studies report that fluoxetine has the maximum volume of distribution (Vd) of any SSRI (between 14 and 100 L/kg).<ref name="statpearls"/><br />
| pk_metabolism = Fluoxetine's active metabolite is norfluoxetine, produced when the cytochrome P450 enzyme (CYP2D6) acts on it. Prescribers must remember that fluoxetine has several drug-drug interactions due to its metabolism through the CYP2D6 isoenzyme. Additionally, norfluoxetine can have an inhibitory effect on CYP3A4. Fluoxetine has a half-life of 2 to 4 days, and its active metabolite norfluoxetine has a half-life of 7 to 9 days. Approximately 7% of individuals definitively exhibit poor metabolism of fluoxetine due to reduced activity of CYP2D6.<br />
| pk_elimination = <br />
| pharmacodynamics = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = None required<br />
| counseling = <br />
| anecdotes = <anecdote slug="2026-05-12" perspective="provider" author="MDElliottMD"><br />
Fluoxetine is great for getting off other SxRIs! Especially venlafaxine and duloxetine.<br />
</anecdote><br />
| seealso = [[Sertraline]], [[Duloxetine]]<br />
| references = <references/><br />
}}<br />
<br />
[[Category:Selective Serotonin Reuptake Inhibitors (SSRIs)]]<br />
[[Category:Antidepressants]]<br />
[[Category:Medicines]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Acacia_confusa&diff=3344
Acacia confusa
2026-05-14T15:07:20Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Acacia confusa<br />
| brand = <br />
| structure = <br />
| classes = Botanical<br />
| mechanism = DMT-containing plant used in psychedelic preparations<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
[[Category:Research Materials]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=5-HTP&diff=3343
5-HTP
2026-05-14T15:07:20Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 5-HTP<br />
| brand = <br />
| structure = <br />
| classes = Nootropic, Oneirogen<br />
| mechanism = Serotonin precursor; 5-hydroxytryptophan<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
[[Category:Research Materials]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=RTI-111&diff=3342
RTI-111
2026-05-14T15:07:19Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = RTI-111<br />
| brand = <br />
| structure = <br />
| classes = Research material, Stimulant<br />
| mechanism = Dopamine reuptake inhibitor; tropane analogue<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
[[Category:Research Materials]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=MCPP&diff=3341
MCPP
2026-05-14T15:07:19Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = mCPP<br />
| brand = <br />
| structure = <br />
| classes = Research material, Piperazine<br />
| mechanism = 5-HT2C agonist; 5-HT2A antagonist; serotonin releasing agent<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
[[Category:Research Materials]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Nitromethaqualone&diff=3340
Nitromethaqualone
2026-05-14T15:07:19Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Nitromethaqualone<br />
| brand = <br />
| structure = <br />
| classes = Research material, GABAergic<br />
| mechanism = Methaqualone analogue; GABAA potentiator<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
[[Category:Research Materials]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=NM-2-AI&diff=3339
NM-2-AI
2026-05-14T15:07:19Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = NM-2-AI<br />
| brand = <br />
| structure = <br />
| classes = Research material, Stimulant<br />
| mechanism = N-methyl analogue of 2-AI<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
[[Category:Research Materials]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=2-AI&diff=3338
2-AI
2026-05-14T15:07:19Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 2-AI<br />
| brand = <br />
| structure = <br />
| classes = Research material, Stimulant<br />
| mechanism = Alpha-methylated amphetamine analogue; norepinephrine releasing agent<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
[[Category:Research Materials]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Pyrazolam&diff=3337
Pyrazolam
2026-05-14T15:07:19Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Pyrazolam<br />
| brand = <br />
| structure = <br />
| classes = Research material, Benzodiazepine, Anxiolytic<br />
| mechanism = GABAA positive allosteric modulator; low sedation<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Benzodiazepines]]<br />
[[Category:Sedative-Hypnotics]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Nifoxipam&diff=3336
Nifoxipam
2026-05-14T15:07:19Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Nifoxipam<br />
| brand = <br />
| structure = <br />
| classes = Research material, Benzodiazepine, Sedative-Hypnotic<br />
| mechanism = GABAA positive allosteric modulator<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Benzodiazepines]]<br />
[[Category:Sedative-Hypnotics]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Metizolam&diff=3335
Metizolam
2026-05-14T15:07:19Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Metizolam<br />
| brand = <br />
| structure = <br />
| classes = Research material, Thienodiazepine, Anxiolytic<br />
| mechanism = GABAA positive allosteric modulator<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Benzodiazepines]]<br />
[[Category:Sedative-Hypnotics]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Flunitrazolam&diff=3334
Flunitrazolam
2026-05-14T15:07:19Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Flunitrazolam<br />
| brand = <br />
| structure = <br />
| classes = Research material, Benzodiazepine, Sedative-Hypnotic<br />
| mechanism = GABAA positive allosteric modulator<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Benzodiazepines]]<br />
[[Category:Sedative-Hypnotics]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Flubromazolam&diff=3333
Flubromazolam
2026-05-14T15:07:19Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Flubromazolam<br />
| brand = <br />
| structure = <br />
| classes = Research material, Benzodiazepine, Sedative-Hypnotic<br />
| mechanism = Extremely potent GABAA positive allosteric modulator<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Benzodiazepines]]<br />
[[Category:Sedative-Hypnotics]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Flubromazepam&diff=3332
Flubromazepam
2026-05-14T15:07:19Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Flubromazepam<br />
| brand = <br />
| structure = <br />
| classes = Research material, Benzodiazepine, Sedative-Hypnotic<br />
| mechanism = GABAA positive allosteric modulator; very long half-life<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Benzodiazepines]]<br />
[[Category:Sedative-Hypnotics]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Flualprazolam&diff=3331
Flualprazolam
2026-05-14T15:07:19Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Flualprazolam<br />
| brand = <br />
| structure = <br />
| classes = Research material, Benzodiazepine, Sedative-Hypnotic<br />
| mechanism = GABAA positive allosteric modulator<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Benzodiazepines]]<br />
[[Category:Sedative-Hypnotics]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Etizolam&diff=3330
Etizolam
2026-05-14T15:07:18Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Etizolam<br />
| brand = <br />
| structure = <br />
| classes = Research material, Thienodiazepine, Anxiolytic<br />
| mechanism = GABAA positive allosteric modulator<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Benzodiazepines]]<br />
[[Category:Sedative-Hypnotics]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Deschloroetizolam&diff=3329
Deschloroetizolam
2026-05-14T15:07:18Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Deschloroetizolam<br />
| brand = <br />
| structure = <br />
| classes = Research material, Thienodiazepine, Sedative-Hypnotic<br />
| mechanism = GABAA positive allosteric modulator<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Benzodiazepines]]<br />
[[Category:Sedative-Hypnotics]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Diclazepam&diff=3328
Diclazepam
2026-05-14T15:07:18Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Diclazepam<br />
| brand = <br />
| structure = <br />
| classes = Research material, Benzodiazepine, Sedative-Hypnotic<br />
| mechanism = GABAA positive allosteric modulator<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Benzodiazepines]]<br />
[[Category:Sedative-Hypnotics]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Clonazolam&diff=3327
Clonazolam
2026-05-14T15:07:18Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Clonazolam<br />
| brand = <br />
| structure = <br />
| classes = Research material, Benzodiazepine, Sedative-Hypnotic<br />
| mechanism = GABAA positive allosteric modulator<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Benzodiazepines]]<br />
[[Category:Sedative-Hypnotics]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=O-PCE&diff=3326
O-PCE
2026-05-14T15:07:18Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = O-PCE<br />
| brand = <br />
| structure = <br />
| classes = Research material, Dissociative<br />
| mechanism = NMDA antagonist<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Arylcyclohexylamines]]<br />
[[Category:Dissociatives]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Methoxetamine&diff=3325
Methoxetamine
2026-05-14T15:07:18Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Methoxetamine<br />
| brand = <br />
| structure = <br />
| classes = Research material, Dissociative<br />
| mechanism = NMDA antagonist; SERT inhibitor; sigma-1 agonist<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Arylcyclohexylamines]]<br />
[[Category:Dissociatives]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Eticyclidine&diff=3324
Eticyclidine
2026-05-14T15:07:18Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Eticyclidine<br />
| brand = <br />
| structure = <br />
| classes = Research material, Dissociative<br />
| mechanism = NMDA antagonist; more stimulating than PCP<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Arylcyclohexylamines]]<br />
[[Category:Dissociatives]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Deschloroketamine&diff=3323
Deschloroketamine
2026-05-14T15:07:18Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Deschloroketamine<br />
| brand = <br />
| structure = <br />
| classes = Research material, Dissociative<br />
| mechanism = NMDA antagonist; ketamine analogue<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Arylcyclohexylamines]]<br />
[[Category:Dissociatives]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=4-MeO-PCP&diff=3322
4-MeO-PCP
2026-05-14T15:07:18Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 4-MeO-PCP<br />
| brand = <br />
| structure = <br />
| classes = Research material, Dissociative<br />
| mechanism = NMDA antagonist<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Arylcyclohexylamines]]<br />
[[Category:Dissociatives]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=3-MeO-PCP&diff=3321
3-MeO-PCP
2026-05-14T15:07:18Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 3-MeO-PCP<br />
| brand = <br />
| structure = <br />
| classes = Research material, Dissociative<br />
| mechanism = NMDA antagonist; sigma receptor agonist; dopaminergic<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Arylcyclohexylamines]]<br />
[[Category:Dissociatives]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=3-MeO-PCE&diff=3320
3-MeO-PCE
2026-05-14T15:07:18Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 3-MeO-PCE<br />
| brand = <br />
| structure = <br />
| classes = Research material, Dissociative<br />
| mechanism = NMDA antagonist; sigma receptor agonist<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Arylcyclohexylamines]]<br />
[[Category:Dissociatives]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=3-HO-PCP&diff=3319
3-HO-PCP
2026-05-14T15:07:18Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 3-HO-PCP<br />
| brand = <br />
| structure = <br />
| classes = Research material, Dissociative<br />
| mechanism = NMDA antagonist; potent opioid agonist<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Arylcyclohexylamines]]<br />
[[Category:Dissociatives]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=3-HO-PCE&diff=3318
3-HO-PCE
2026-05-14T15:07:18Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 3-HO-PCE<br />
| brand = <br />
| structure = <br />
| classes = Research material, Dissociative<br />
| mechanism = NMDA antagonist; opioid agonist<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Arylcyclohexylamines]]<br />
[[Category:Dissociatives]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=2-FDCK&diff=3317
2-FDCK
2026-05-14T15:07:17Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 2-FDCK<br />
| brand = <br />
| structure = <br />
| classes = Research material, Dissociative<br />
| mechanism = NMDA antagonist; fluorinated ketamine analogue<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Arylcyclohexylamines]]<br />
[[Category:Dissociatives]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Methylnaphthidate&diff=3316
Methylnaphthidate
2026-05-14T15:07:17Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Methylnaphthidate<br />
| brand = <br />
| structure = <br />
| classes = Research material, Phenidate, Stimulant<br />
| mechanism = Dopamine/norepinephrine reuptake inhibitor<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Methylphenidates (Phenidates)]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Isopropylphenidate&diff=3315
Isopropylphenidate
2026-05-14T15:07:17Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Isopropylphenidate<br />
| brand = <br />
| structure = <br />
| classes = Research material, Phenidate, Stimulant<br />
| mechanism = Dopamine/norepinephrine reuptake inhibitor<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Methylphenidates (Phenidates)]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Ethylphenidate&diff=3314
Ethylphenidate
2026-05-14T15:07:17Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Ethylphenidate<br />
| brand = <br />
| structure = <br />
| classes = Research material, Phenidate, Stimulant<br />
| mechanism = Dopamine/norepinephrine reuptake inhibitor<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Methylphenidates (Phenidates)]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=4F-MPH&diff=3313
4F-MPH
2026-05-14T15:07:17Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 4F-MPH<br />
| brand = <br />
| structure = <br />
| classes = Research material, Phenidate, Stimulant<br />
| mechanism = Dopamine/norepinephrine reuptake inhibitor<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Methylphenidates (Phenidates)]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=4F-EPH&diff=3312
4F-EPH
2026-05-14T15:07:17Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 4F-EPH<br />
| brand = <br />
| structure = <br />
| classes = Research material, Phenidate, Stimulant<br />
| mechanism = Dopamine/norepinephrine reuptake inhibitor<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Methylphenidates (Phenidates)]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=3,4-CTMP&diff=3311
3,4-CTMP
2026-05-14T15:07:17Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 3,4-CTMP<br />
| brand = <br />
| structure = <br />
| classes = Research material, Phenidate, Stimulant<br />
| mechanism = Potent dopamine/norepinephrine reuptake inhibitor<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Methylphenidates (Phenidates)]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=4-FMA&diff=3310
4-FMA
2026-05-14T15:07:17Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 4-FMA<br />
| brand = <br />
| structure = <br />
| classes = Research material, Amphetamine, Stimulant<br />
| mechanism = Monoamine releasing agent<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Amphetamines]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=4-FA&diff=3309
4-FA
2026-05-14T15:07:17Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 4-FA<br />
| brand = <br />
| structure = <br />
| classes = Research material, Amphetamine, Stimulant, Empathogen<br />
| mechanism = Monoamine releasing agent; serotonergic at higher doses<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Amphetamines]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=3-FMA&diff=3308
3-FMA
2026-05-14T15:07:17Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 3-FMA<br />
| brand = <br />
| structure = <br />
| classes = Research material, Amphetamine, Stimulant<br />
| mechanism = Monoamine releasing agent<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Amphetamines]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=3-FA&diff=3307
3-FA
2026-05-14T15:07:17Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 3-FA<br />
| brand = <br />
| structure = <br />
| classes = Research material, Amphetamine, Stimulant<br />
| mechanism = Monoamine releasing agent<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Amphetamines]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=2-FMA&diff=3306
2-FMA
2026-05-14T15:07:17Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 2-FMA<br />
| brand = <br />
| structure = <br />
| classes = Research material, Amphetamine, Stimulant<br />
| mechanism = Monoamine releasing agent<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Amphetamines]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=2-FA&diff=3305
2-FA
2026-05-14T15:07:16Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = 2-FA<br />
| brand = <br />
| structure = <br />
| classes = Research material, Amphetamine, Stimulant<br />
| mechanism = Monoamine releasing agent<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Amphetamines]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=MDPV&diff=3304
MDPV
2026-05-14T15:07:16Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = MDPV<br />
| brand = <br />
| structure = <br />
| classes = Research material, Pyrrolidinophenone, Stimulant<br />
| mechanism = Potent dopamine and norepinephrine reuptake inhibitor<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Cathinones]]<br />
[[Category:Pyrrolidinophenones]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Alpha-PVP&diff=3303
Alpha-PVP
2026-05-14T15:07:16Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = alpha-PVP<br />
| brand = <br />
| structure = <br />
| classes = Research material, Pyrrolidinophenone, Stimulant<br />
| mechanism = Dopamine and norepinephrine reuptake inhibitor<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Cathinones]]<br />
[[Category:Pyrrolidinophenones]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Alpha-PHP&diff=3302
Alpha-PHP
2026-05-14T15:07:16Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = alpha-PHP<br />
| brand = <br />
| structure = <br />
| classes = Research material, Pyrrolidinophenone, Stimulant<br />
| mechanism = Dopamine and norepinephrine reuptake inhibitor<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Cathinones]]<br />
[[Category:Pyrrolidinophenones]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=Pentedrone&diff=3301
Pentedrone
2026-05-14T15:07:16Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = Pentedrone<br />
| brand = <br />
| structure = <br />
| classes = Research material, Cathinone, Stimulant<br />
| mechanism = Norepinephrine/dopamine reuptake inhibitor<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Cathinones]]<br />
[[Category:Pyrrolidinophenones]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=N-Ethylpentedrone&diff=3300
N-Ethylpentedrone
2026-05-14T15:07:16Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = N-Ethylpentedrone<br />
| brand = <br />
| structure = <br />
| classes = Research material, Cathinone, Stimulant<br />
| mechanism = Cathinone analogue; monoamine reuptake inhibitor<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Cathinones]]<br />
[[Category:Pyrrolidinophenones]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default
https://pharmacopedia.wiki/index.php?title=N-Ethylhexedrone&diff=3299
N-Ethylhexedrone
2026-05-14T15:07:16Z
<p>MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines</p>
<hr />
<div>{{MedTemplate<br />
| generic = N-Ethylhexedrone<br />
| brand = <br />
| structure = <br />
| classes = Research material, Cathinone, Stimulant<br />
| mechanism = Norepinephrine/dopamine releasing agent<br />
| uses = <br />
| starting_dose = <br />
| preparations = <br />
| fda_max = <br />
| routes = <br />
| onset = <br />
| duration = <br />
| halflife = <br />
| bioavailability = <br />
| pregnancy = <br />
| legal = <br />
| intro = <br />
| pharmacokinetics = <br />
| pharmacodynamics = <br />
| indications = <br />
| dosing = <br />
| effects = <br />
| interactions = <pharmaInteractions/><br />
| pregnancy_details = <br />
| monitoring = <br />
| counseling = <br />
| anecdotes = <br />
| seealso = <br />
| references = <br />
}}<br />
<br />
<br />
[[Category:Research Materials]]<br />
[[Category:Cathinones]]<br />
[[Category:Pyrrolidinophenones]]<br />
[[Category:Psychostimulants]]</div>
MediaWiki default